IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection

Molecular Carcinogenesis

Volumn 53, Issue 6, 2014, Pages 447-457

  Li, Na ^a   Zhu, Qianqian ^a   Li, Zhu ^a   Han, Qunying ^a   Zhang, Guoyu ^a   Chen, Jinghong ^a   Lv, Yi ^a   Xing, Fanfan ^a   Chen, Yanping ^a   Zeng, Xiaoyan ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Association; Chronic HBV infection; HCC; IgE; IL 17A; IL17A polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 17;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC HEPATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEPATITIS B; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATITIS B VIRUS;

ASSOCIATION; CHRONIC HBV INFECTION; HCC; IGE; IL-17A; IL17A POLYMORPHISM;

ADULT; ALLELES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOTYPE; HAPLOTYPES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN E; INTERLEUKIN-17; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS;

EID: 84899924921     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21992     Document Type: Article

References (63)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129.
2. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442-3449.
3. Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25:1022-1027.
4. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191:1269-1280.
5. Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52:330-339.
6. Zhang G, Li Z, Han Q, et al. Altered TNF-α and IFN-γ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infect Genet Evol 2011; 11:1624-1630.
7. Yu Y, Gong R, Mu Y, et al. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol 2011; 187:4844-4860.
8. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004; 114:1265-1273.
9. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-476.
10. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-1914.
11. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132.
12. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
13. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-189.
14. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-1141.
15. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821-852.
16. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009; 11:625-630.
17. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-286.
18. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007; 178:6730-6733.
19. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 2008; 105:15505-15510.
20. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57:772-779.
21. Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51:81-91.
22. Wu W, Li J, Chen F, Zhu H, Peng G, Chen Z. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol 2010; 25:750-757.
23. Ye Y, Xie X, Yu J, et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol 2010; 30:546-555.
24. Wang L, Chen S, Xu K. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int J Mol Med 2011; 27:385-392.
25. Wang WW, Wang ZM, Liu YY, Qin YH, Shen Q. Increased level of Th17 cells in peripheral blood correlates with the development of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi (Chin J Oncol) 2010; 32:757-761 (in Chinese).
26. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50:980-989.
27. Li J, Lau GK, Chen L, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS ONE 2011; 6:e21816.
28. Nordang GB, Viken MK, Hollis-Moffatt JE, et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford) 2009; 48:367-370.
29. Arisawa T, Tahara T, Shibata T, et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008; 28:44-49.
30. Kim SW, Kim ES, Moon CM, et al. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut 2011; 60:1527-1536.
31. Wang JY, Shyur SD, Wang WH, et al. The polymorphisms of interleukin 17A (IL17A) gene and its association with pediatric asthma in Taiwanese population. Allergy 2009; 64:1056-1060.
32. Espinoza JL, Takami A, Nakata K, et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 2011; 6:e26229.
33. Carvalho A, Cunha C, Di Ianni M, et al. Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 2010; 45:1645-1652.
34. Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol 2009; 70:547-551.
35. Wang L, Jiang Y, Zhang Y, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS ONE 2012; 7:e34400.
36. Levo Y, Shalit M. Serum IgE levels in patients with liver disease. Ann Allergy 1981; 47:456-459.
37. Gutiérrez D, Guardia P, Delgado J, et al. Increased serum IgE in acute type A, B and delta hepatitis. J Investig Allergol Clin Immunol 1997; 7:119-121.
38. Abbott W, Gane E, Winship I, Munn S, Tukuitonga C. Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics 2007; 59:187-195.
39. Milovanovic M, Drozdenko G, Weise C, Babina M, Worm M. Interleukin-17A promotes IgE production in human B cells. J Invest Dermatol 2010; 130:2621-2628.
40. Nigro EA, Brini AT, Soprana E, et al. Antitumor IgE adjuvanticity: Key role of Fc epsilon RI. J Immunol 2009; 183:4530-4536.
41. Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 2008; 63:1255-1266.
42. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
43. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127:S126-S132.
44. Bruix J, Sherman M, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: An update. Hepatology 2011; 53:1020-1022.
45. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4:439-474.
46. Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol 2009; 104:2206-2213.
47. Tsang PS, Trinh H, Garcia RT, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008; 6:569-574.
48. Hu KQ, Schiff ER, Kowdley KV, et al. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroenterol 2010; 44:510-516.
49. Seto WK, Lai CL, Ip PP, et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS ONE 2012; 7:e32622.
50. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15:97-98.
51. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: Special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14:147-152.
52. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int 2008; 2:28-36.
53. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186:295-301.
54. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-2137.
55. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86:1143-1150.
56. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50:80-88.
57. Wan DW, Tzimas D, Smith JA, et al. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol 2011; 106:1994-2000.
58. Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 2011; 41:2314-2322.
59. Kuang DM, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54:948-955.
60. Oliviero B, Cerino A, Varchetta S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 2011; 55:53-60.
61. Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42:755-758.
62. Zhong R, Tian Y, Liu L, et al. HBV-related hepatocellular carcinoma susceptibility gene KIF1B is not associated with development of chronic hepatitis B. PLoS ONE 2012; 7:e28839.
63. Sawai H, Nishida N, Mbarek H, et al. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet 2012; 13:47.